ClinicalTrials.gg
CompletedNCT01134042Updated Jan 11, 2017Results posted

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol Inhalation Powder and Fluticasone Furoate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 71 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
587
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
34th of 238
587 · median 93
Started
2010
with 33 others
Phase 3
61 of 262
6 open now
Registered
93rd of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 34th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 93rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Fluticasone propionate
  • asthma
  • vilanterol
  • GW642444
  • Fluticasone furoate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient at least 12 years of age
  • Both genders; females of must be willing to use method
  • Pre-bronchodilator of 40-90% predicted
  • Reversibility FEV1 of at least 12% and 200mls
  • Current asthma therapy that includes an inhaled for at least 12 weeks prior to first visit

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma
  • Respiratory infection or oral candidiasis
  • Asthma exacerbation within 12 weeks
  • Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drugs' , medications related to study drugs
  • Taking another medication or medication prohibited for use during this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
587 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol

    Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks

    Drug: Fluticasone Furoate/Vilanterol Inhalation Powder · Other: Placebo Inhalation Powder 2

  • Active comparator
    Fluticasone Furoate

    Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks

    Drug: Fluticasone Furoate Inhalation Powder · Other: Placebo Inhalation Powder 2

  • Active comparator
    Fluticasone Propionate

    Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks

    Drug: Fluticasone Propionate Inhalation Powder · Other: Placebo Inhalation Powder 1

Interventions

  • DrugFluticasone Furoate/Vilanterol Inhalation Powder

    Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks

  • DrugFluticasone Furoate Inhalation Powder

    Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks

  • DrugFluticasone Propionate Inhalation Powder

    Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks

  • OtherPlacebo Inhalation Powder 1

    Placebo in novel dry powder inhaler once daily

  • OtherPlacebo Inhalation Powder 2

    Placebo in Diskus inhaler twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the clinic visit while still on treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline (BL) through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. BL was the pre-dose value obtained at Visit 3. Change from BL was calculated as the Week 24 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of BL trough FEV1, country, sex, age, and treatment group.The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-BL on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 24 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 5 minutes prior to dosing) and the post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 24 FEV1 value minus the Baseline value.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in the Percentage of Rescue-free and Symptom-free 24-hour Periods at the End of the 24-week Treatment Period

    The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication/symptoms was considered to be rescue free/symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value.

    Time frame: Baseline and Week 24

  2. Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24/Early Withdrawal

    The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Weeks 12 and 24 minus the total score at Baseline.

    Time frame: Baseline, Week 12, and Week 24/Early Withdrawal

Other outcomes

  1. Clinic Visit 12-hour Post-dose FEV1at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 24 clinic visit. The highest of 3 technically acceptable measurements was recorded.

    Time frame: Week 24

  2. Change From Baseline in Weighted Mean Serial FEV1 Over 0 to 4 Hours Post-dose at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 4-hour serial FEV1 measurements that included the pre-dose assessment (within 5 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 24 FEV1 value minus the Baseline value.

    Time frame: Baseline and Week 24

  3. Mean Change From Baseline in Daily Morning Trough (AM) and Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough AM/PM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value.

    Time frame: From Baseline up to Week 12 and Week 24

  4. The Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period

    The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

    Time frame: From the first dose of the study medication up to Week 24/Early Withdrawal

  5. Change From Baseline in the Asthma Control Test (ACT) Scores at Week 12 and Week 24

    The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12 and Week 24/Early Withdrawal minus the total score at Baseline.

    Time frame: Baseline, Week 12, and Week 24/Early Withdrawal

  6. Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at Weeks 4, 12, and 24

    At the end of Week 4, Week 8, and Week 24/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptoms); much less often, somewhat less often, a little less often, the same, a little more often, somewhat more often, much more often (to assess the changes in the frequency of rescue medication use).

    Time frame: Week 4, Week 12, and Week 24/Early Withdrawal

  7. Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period

    All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare issues were recorded.

    Time frame: From Baseline up to Week 24/Withdrawal Visit

07

Results

Posted Aug 8, 2013

Participant flow

Participant flow — Overall Study
MilestoneFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Started194197195
Completed146169161
Not completed482834
Withdrew: Adverse event372
Withdrew: Lack of efficacy21618
Withdrew: Protocol violation535
Withdrew: Lost to follow-up201
Withdrew: Physician decision481
Withdrew: Withdrawal by subject1347

Outcome measures

PrimaryChange From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the clinic visit while still on treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline (BL) through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. BL was the pre-dose value obtained at Visit 3. Change from BL was calculated as the Week 24 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of BL trough FEV1, country, sex, age, and treatment group.The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-BL on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
LitersFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period0.201 ± 0.03030.394 ± 0.03020.183 ± 0.0300
Statistical analysis
  • FF 200 µg OD vs FF/VI 200/25 µg OD · ANCOVA · p = <0.001 · Median difference (final values): 0.193 · 95% CI 0.108 to 0.277
  • FF/VI 200/25 µg OD vs FP 500 µg BID · ANCOVA · p = <0.001 · Median difference (final values): 0.210 · 95% CI 0.127 to 0.294
  • FF 200 µg OD vs FP 500 µg BID · Median difference (final values): 0.018 · 95% CI -0.066 to 0.102
PrimaryChange From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 24 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 5 minutes prior to dosing) and the post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 24 FEV1 value minus the Baseline value.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 24
LitersFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 240.328 ± 0.04930.464 ± 0.04700.258 ± 0.0483
Statistical analysis
  • FF 200 µg OD vs FF/VI 200/25 µg OD · ANCOVA · p = 0.048 · Mean difference (final values): 0.136 · 95% CI 0.001 to 0.270
  • FF/VI 200/25 µg OD vs FP 500 µg BID · ANCOVA · p = 0.003 · Median difference (final values): 0.206 · 95% CI 0.073 to 0.339
SecondaryChange From Baseline in the Percentage of Rescue-free and Symptom-free 24-hour Periods at the End of the 24-week Treatment Period

The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication/symptoms was considered to be rescue free/symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of periods
Change From Baseline in the Percentage of Rescue-free and Symptom-free 24-hour Periods at the End of the 24-week Treatment Period
Percentage of periodsFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Rescue-free 24-hour periods26.6 ± 2.4538.2 ± 2.4231.9 ± 2.45
Symptom-free 24-hour periods21.0 ± 2.3229.3 ± 2.2924.5 ± 2.31
SecondaryChange From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24/Early Withdrawal

The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Weeks 12 and 24 minus the total score at Baseline.

Time frame:
Baseline, Week 12, and Week 24/Early Withdrawal
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24/Early Withdrawal
Scores on a scaleFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Week 12, n=154, 180, 1630.66 ± 0.0610.74 ± 0.0560.74 ± 0.059
Week 24, n=140, 167, 1560.88 ± 0.0710.93 ± 0.0650.90 ± 0.068
Other pre-specifiedClinic Visit 12-hour Post-dose FEV1at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 24 clinic visit. The highest of 3 technically acceptable measurements was recorded.

Time frame:
Week 24
Reported as:
Mean · Liters
Clinic Visit 12-hour Post-dose FEV1at Week 24
LitersFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Clinic Visit 12-hour Post-dose FEV1at Week 242.611 ± 0.84372.683 ± 0.97582.262 ± 0.7786
Other pre-specifiedChange From Baseline in Weighted Mean Serial FEV1 Over 0 to 4 Hours Post-dose at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 4-hour serial FEV1 measurements that included the pre-dose assessment (within 5 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 24 FEV1 value minus the Baseline value.

Time frame:
Baseline and Week 24
Reported as:
Mean · Liters
Change From Baseline in Weighted Mean Serial FEV1 Over 0 to 4 Hours Post-dose at Week 24
LitersFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Change From Baseline in Weighted Mean Serial FEV1 Over 0 to 4 Hours Post-dose at Week 240.363 ± 0.46900.492 ± 0.56710.256 ± 0.4679
Other pre-specifiedMean Change From Baseline in Daily Morning Trough (AM) and Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough AM/PM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value.

Time frame:
From Baseline up to Week 12 and Week 24
Reported as:
Least squares mean · Liters/minute (L/min)
Mean Change From Baseline in Daily Morning Trough (AM) and Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
Liters/minute (L/min)FF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
AM PEF, Week 1 to 12, n=193, 197, 19515.1 ± 2.8248.1 ± 2.7817.1 ± 2.80
AM PEF, Week 1 to 24, n=193, 197, 19518.2 ± 2.9751.8 ± 2.9418.8 ± 2.95
PM PEF, Week 1 to 12, 192, 197, 1947.5 ± 2.8036.6 ± 2.7512.6 ± 2.78
PM PEF, Week 1 to 24, 192, 197, 1949.1 ± 2.9839.8 ± 2.9313.6 ± 2.96
Other pre-specifiedThe Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period

The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

Time frame:
From the first dose of the study medication up to Week 24/Early Withdrawal
Reported as:
Number · participants
The Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period
participantsFF 200 µg OD ArmFF/VI 200/25 µg ODFP 500 µg BID
The Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period21618
Other pre-specifiedChange From Baseline in the Asthma Control Test (ACT) Scores at Week 12 and Week 24

The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12 and Week 24/Early Withdrawal minus the total score at Baseline.

Time frame:
Baseline, Week 12, and Week 24/Early Withdrawal
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Asthma Control Test (ACT) Scores at Week 12 and Week 24
Scores on a scaleFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Week 12, n=164, 183, 1693.9 ± 0.294.8 ± 0.273.9 ± 0.28
Week 24, n=147, 170, 1625.2 ± 0.305.5 ± 0.284.7 ± 0.29
Other pre-specifiedNumber of Participants With the Indicated Global Assessment of Change Questionnaire Responses at Weeks 4, 12, and 24

At the end of Week 4, Week 8, and Week 24/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptoms); much less often, somewhat less often, a little less often, the same, a little more often, somewhat more often, much more often (to assess the changes in the frequency of rescue medication use).

Time frame:
Week 4, Week 12, and Week 24/Early Withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at Weeks 4, 12, and 24
participantsFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Week 4, AS: Much better, n=174, 191, 180375835
Week 4, AS: Somewhat better, n=174, 191, 180476549
Week 4, AS: A little better, n=174, 191, 180433440
Week 4, AS: The same, n=174, 191, 180352544
Week 4, AS: A little worse, n=174, 191, 180876
Week 4, AS: Somewhat worse, n=174, 191, 180223
Week 4, AS: Much worse, n=174, 191, 180203
Week 4, RMU: Much less often, n=174, 191, 180497142
Week 4, RMU: Somewhat less often, n=174, 191, 180294841
Week 4, RMU: A little less often, n=174, 191, 180423845
Week 4, RMU: The same, n=174, 191, 180342737
Week 4, RMU: A little more often, n=174, 191, 1801449
Week 4, RMU: Somewhat more often, n=174, 191, 180523
Week 4, RMU: Much more often, n=174, 191, 180113
Week 12, AS: Much better, n=162, 183, 165607854
Week 12, AS: Somewhat better, n=162, 183, 165435152
Week 12, AS: A little better, n=162, 183, 165273334
Week 12, AS: The same, n=162, 183, 165231516
Week 12, AS: A little worse, n=162, 183, 165856
Week 12, AS: Somewhat worse, n=162, 183, 165013
Week 12, AS: Much worse, n=162, 183, 165100
Week 12, RMU: Much less often, n=162, 183, 164669059
Week 12, RMU: Somewhat less often, n=162, 183, 164313637
Week 12, RMU: A little less often, n=162, 183, 164282440
Week 12, RMU: The same, n=162, 183, 164262420
Week 12, RMU: A little more often, n=162, 183, 164786
Week 12, RMU: Somewhat more often, n=162, 183, 164201
Week 12, RMU: Much more often, n=162, 183, 164211
Week 24, AS: Much better, n=146, 168, 162648962
Week 24, AS: Somewhat better, n=146, 168, 162433752
Week 24, AS: A little better, n=146, 168, 162222317
Week 24, AS: The same, n=146, 168, 162111423
Week 24, AS: A little worse, n=146, 168, 162344
Week 24, AS: Somewhat worse, n=146, 168, 162212
Week 24, AS: Much worse, n=146, 168, 162102
Week 24, RMU: Much less often, n=146, 168, 162688769
Week 24, RMU: Somewhat less often, n=150, 187, 18333837
Week 24, RMU: A little less often, n=150, 187, 18292226
Week 24, RMU: The same, n=146, 168, 162121619
Week 24, RMU: A little more often, n= 142, 168, 16138
Week 24, RMU: Somewhat more often, n=146, 168, 162311
Week 24, RMU: Much more often, n=146, 168, 162012
Other pre-specifiedNumber of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period

All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare issues were recorded.

Time frame:
From Baseline up to Week 24/Withdrawal Visit
Reported as:
Mean · Number of visits
Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period
Number of visitsFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
Number of Home Visits (Day)0.0 ± 0.070.0 ± 0.000.0 ± 0.00
Number of Home Visits (Night)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Physician Office/Practice Visits0.0 ± 0.100.0 ± 0.000.1 ± 0.45
Number of Urgent Care/Outpatient Clinic Visits0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Emergency Room Visits0.0 ± 0.070.0 ± 0.000.0 ± 0.00
Number of Inpatient Hospitalization Days (ICU)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Inpatient Hospitalization (GW) Days0.0 ± 0.290.0 ± 0.000.0 ± 0.00

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the the treatment period (up to Week 24).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 200 µg OD—1/194 (0.5%)66/194 (34%)
FF/VI 200/25 µg OD—6/197 (3%)62/197 (31.5%)
FP 500 µg BID—2/195 (1%)73/195 (37.4%)
Most frequent serious events
Most frequent serious events
EventFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
AsthmaRespiratory, thoracic and mediastinal disorders1/1940/1970/195
Lower limb fractureInjury, poisoning and procedural complications0/1940/1971/195
HaemoptysisRespiratory, thoracic and mediastinal disorders0/1940/1971/195
Limb traumatic amputationInjury, poisoning and procedural complications0/1941/1970/195
Atrial fibrillationCardiac disorders0/1941/1970/195
Inguinal herniaGastrointestinal disorders0/1941/1970/195
PneumoniaInfections and infestations0/1941/1970/195
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1941/1970/195
HaematuriaRenal and urinary disorders0/1941/1970/195
Most frequent other events
Showing 10 of 11
Most frequent other events
EventFF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BID
NasopharyngitisInfections and infestations27/19425/19739/195
HeadacheNervous system disorders13/19411/19715/195
CoughRespiratory, thoracic and mediastinal disorders6/1943/19713/195
InfluenzaInfections and infestations8/1945/1977/195
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/1944/1977/195
Respiratory tract infection viralInfections and infestations7/1947/1977/195
SinusitisInfections and infestations7/1943/1974/195
RhinitisInfections and infestations2/1941/1977/195
BronchitisInfections and infestations6/1947/1976/195
PharyngitisInfections and infestations2/1944/1976/195

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BIDTotal
Mean44.6 ± 14.3346.6 ± 15.0547.3 ± 14.0646.2 ± 14.51
Gender
Gender(Participants)FF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BIDTotal
Female113116116345
Male818179241
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FF 200 µg ODFF/VI 200/25 µg ODFP 500 µg BIDTotal
African American/African Heritage (HER)16161951
American Indian or Alaska Native0011
Japanese/East Asian HER/South East Asian HER12151340
White165165162492
African American/African Heritage and White1102
08

Study locations

71 sites
  • GSK Investigational Site
    Bell Gardens, California 90201, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Panama City, Florida 32405, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    River Forest, Illinois 60305, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78756, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Cottbus, Brandenburg 03050, Germany
  • GSK Investigational Site
    Schwedt, Brandenburg 16303, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Kassel, Hessen 34121, Germany
  • GSK Investigational Site
    Ruesselsheim, Hessen 65428, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30167, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Hamburg, 20354, Germany
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Hiroshima, 732-0052, Japan
  • GSK Investigational Site
    Hyogo, 672-8048, Japan
  • GSK Investigational Site
    Ishikawa, 920-8530, Japan
  • GSK Investigational Site
    Kagawa, 762-0031, Japan
  • GSK Investigational Site
    Kyoto, 603-8161, Japan
  • GSK Investigational Site
    Okayama, 712-8064, Japan
  • GSK Investigational Site
    Okinawa, 901-2132, Japan
  • GSK Investigational Site
    Shizuoka, 430-8558, Japan
  • GSK Investigational Site
    Shizuoka, 438-8550, Japan
  • GSK Investigational Site
    Tokyo, 105-0003, Japan
  • GSK Investigational Site
    Tokyo, 158-0083, Japan
  • GSK Investigational Site
    Bialystok, 15-010, Poland
  • GSK Investigational Site
    Dzialdowo, 13-200, Poland
  • GSK Investigational Site
    Gdansk, 80-169, Poland
  • GSK Investigational Site
    Gdansk, 84-462, Poland
  • GSK Investigational Site
    Gliwice, 44-100, Poland
  • GSK Investigational Site
    Krakow, 31-202, Poland
  • GSK Investigational Site
    Piekary Slaskie, 41-940, Poland
  • GSK Investigational Site
    Sopot, 81-741, Poland
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 030317, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
  • GSK Investigational Site
    Oradea, 410176, Romania
  • GSK Investigational Site
    Ploiesti, 100550, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Ekaterinburg, 620109, Russian Federation
  • GSK Investigational Site
    Kazan, 420015, Russian Federation
  • GSK Investigational Site
    Moscow, 115 280, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Moscow, 123182, Russian Federation
  • GSK Investigational Site
    Moscow, 125367, Russian Federation
  • GSK Investigational Site
    Moscow, 127018, Russian Federation
  • GSK Investigational Site
    Ryazan,, 390026, Russian Federation
  • GSK Investigational Site
    Smolensk, 214001, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 198216, Russian Federation
  • GSK Investigational Site
    Yaroslavl, Russian Federation
09

References and documents

Publications

  • Kosinski M, Nelsen L, Rizio AA, Lay-Flurrie J, von Maltzahn R, Jacques L, Schatz M, Stanford RH, Svedsater H. Psychometric properties of the Asthma Control Test in 2 randomized clinical trials. J Allergy Clin Immunol Pract. 2021 Jan;9(1):561-563.e1. doi: 10.1016/j.jaip.2020.07.040. Epub 2020 Aug 6. No abstract available. PubMed 32771685 ↗
  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗
  • Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z. PubMed 26704701 ↗
  • O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lotvall J. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014 Mar;43(3):773-82. doi: 10.1183/09031936.00064513. Epub 2013 Oct 17. PubMed 24136330 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 10 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
May 31, 2010
Start
Jun 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Apr 26, 2012
Results first posted
Aug 8, 2013
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01134042
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 31, 2010
Start date
Jun 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Aug 8, 2013
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion